COMMUNIQUÉS West-GlobeNewswire
-
PhaseBio To Report Third Quarter 2018 Financial and Business Results on November 29, 2018
21/11/2018 - 14:00 -
VBL Therapeutics to Present at the Piper Jaffray 30th Annual Healthcare Conference on November 28
21/11/2018 - 14:00 -
Abattis Retains Canadian and American Compliance Agency and Provides Company Update
21/11/2018 - 14:00 -
BioSyent Releases Results for Third Quarter and First Nine Months of 2018
21/11/2018 - 14:00 -
Nexstim Plc's resolutions of the Extraordinary General Meeting of Shareholders
21/11/2018 - 13:01 -
CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference
21/11/2018 - 13:00 -
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
21/11/2018 - 13:00 -
Aleafia and Serruya Private Equity Reach Agreement for National Retail Dispensary, top Performing Brands and $10M Investment
21/11/2018 - 13:00 -
Clementia to Present at the Evercore ISI HealthCONx Conference
21/11/2018 - 12:30 -
Clementia annonce qu’elle participera à la Conférence Evercore ISI HealthCONx (« Evercore ISI HealthCONx Conference »)
21/11/2018 - 12:30 -
HEXO Announces Filing Of Final Base Shelf Prospectus
21/11/2018 - 12:30 -
HEXO annonce le dépôt d’un prospectus préalable de base définitif
21/11/2018 - 12:30 -
OraSure Technologies to Present at the 30th Annual Piper Jaffray Healthcare Conference
21/11/2018 - 12:00 -
Eckert & Ziegler BEBIG: Convening Notice of the Extraordinary General Meeting of Shareholders
21/11/2018 - 11:38 -
Eckert & Ziegler BEBIG: Convocation à l'assemblée générale extraordinaire des actionnaires
21/11/2018 - 11:38 -
TLC Announces Pricing of Initial Public Offering of American Depositary Shares (ADSs) on Nasdaq
21/11/2018 - 10:39 -
The Phase III study protocol is modified after IBT’s meeting with the FDA
21/11/2018 - 09:45 -
LIDDS adds two major university clinics in Lithuania to speed up enrollment in ongoing Phase IIb study
21/11/2018 - 08:46 -
UPDATE - BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
21/11/2018 - 00:54
Pages